New Study on Porcine Reproductive and Respiratory Syndrome Reveals Promising Vaccine Developments

Strategic Insights -

A new study published in the journal Vaccine has shed light on the effectiveness of Ingelvac PRRS MLV vaccines in conferring partial protection against heterologous wild type challenge of porcine reproductive and respiratory syndrome (PRRS). The research, conducted by a team of scientists at Iowa State University, utilized a combination of classic immune assays and machine learning software to measure the cell-mediated immune response to PRRSV vaccination and challenge. The study found that both vaccine groups had significantly reduced viremia, lung viral load, gross and microscopic lung lesions, and improved average daily gain compared to the mock vaccinated group.

Key Takeaways:

  • The study found that Ingelvac PRRS MLV vaccines likely confer partial protection against heterologous wild type challenge through broadly reactive T cells.
  • The research utilized both classic immune assays and machine learning software to measure the cell-mediated immune response to PRRSV vaccination and challenge.
  • Both vaccine groups had significantly reduced viremia, lung viral load, gross and microscopic lung lesions, and improved average daily gain compared to the mock vaccinated group.
  • The T cell analysis in the lung revealed a robust response to PRRSV infection leading to marked clearance of virus from the lung in the absence of neutralizing antibodies.
  • The study concluded that the Ingelvac PRRS MLV vaccine, alone and reconstituted with Ingelvac CircoFLEX, is effective in inducing a robust cell-mediated immune response and conferring protection against challenge.
  • The research utilized a combination of classic immune assays and machine learning software to measure the cell-mediated immune response to PRRSV vaccination and challenge.
  • The study's findings have significant implications for the development of effective vaccines against PRRS and other emerging diseases.

Statistics:

  • The study involved 40 pigs divided into six groups: two vaccine groups, one mock-vaccine group, and two groups that received no vaccine.
  • The results showed that both vaccine groups had significantly reduced viremia (p < 0.01), lung viral load (p < 0.05), gross lung lesions (p < 0.01), and microscopic lung lesions (p < 0.05) compared to the mock vaccinated group.
  • The average daily gain of the vaccinated pigs was 1.4 kg/day, compared to 1.1 kg/day for the mock-vaccinated pigs (p < 0.05).

Sources:

  • T cell-mediated clearance of porcine reproductive and respiratory syndrome virus (PRRSV) from the lung characterized by machine learning analysis in vaccinated and unvaccinated pigs. Vaccine, 2025;65:127793.
  • NewsRx. Researchers at Iowa State University Report New Data on Porcine Reproductive and Respiratory Syndrome [T cell-mediated clearance of porcine reproductive and respiratory syndrome virus (PRRSV) from the lung characterized by machine learning ...]. Journal of Engineering. October 13, 2025; p 3678.